Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings
Open Access
- 20 March 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1302-e1310
Abstract
Background: Some patients who test trace positive on Xpert MTB/RIF Ultra (“Ultra”), a highly sensitive molecular diagnostic platform, may not have tuberculosis (TB) disease. A better understanding of the prevalence of TB, associated clinical characteristics, and utility of additional diagnostic tests among people with trace sputum (PWTS) could aid clinical decision-making. Methods: We enrolled adults and adolescents with trace-positive sputum on initial TB diagnostic evaluation in Uganda and South Africa. Participants were extensively evaluated at enrollment; those with uncertain TB status were followed off treatment, with interval reevaluations by TB clinicians, for up to 3 months. We assessed TB prevalence and associated patient characteristics and diagnostic results. Results: Among 311 PWTS, TB was identified by sputum culture at enrollment in 20% of participants (61/311, 95% CI 15%–24%). Within 3 months, 48% (145/301, 95% CI 43%–54%) had been judged to warrant TB treatment, and among those followed until microbiologic outcomes, 30% (68/227, 95% CI 24%–36%) had positive culture and 41% (99/240, 95% CI 35%–47%) had positive culture or Ultra. Two participants died. Having TB symptoms, advanced human immunodeficiency virus (HIV), and no recent TB history were associated with microbiologically confirmed TB disease, as were an abnormal chest X-ray (in those without recent TB) or elevated C-reactive protein (CRP). Conclusions: Roughly half of PWTS were recommended TB therapy. This prevalence supports treating most PWTS when multimodal testing and repeated clinical evaluations are infeasible. However, given low observed mortality, some people with low-risk characteristics and negative results on other widely available diagnostic tests could safely defer treatment with clinical follow-up.Keywords
Funding Information
- National Institutes of Health (R01HL153611)
- Gates Family Foundation (INV-042921)
- Gates Family Foundation (OPP1213504)
This publication has 14 references indexed in Scilit:
- Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exerciseThe Lancet Respiratory Medicine, 2024
- Evaluating systematic targeted universal testing for tuberculosis in primary care clinics of South Africa: A cluster-randomized trial (The TUTT Trial)PLOS Medicine, 2023
- The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysisThe Lancet Respiratory Medicine, 2023
- Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South AfricaBMJ Open, 2022
- Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, BangladeshInternational Journal of Infectious Diseases, 2022
- Tracing TB: Are there predictors for active TB disease in patients with Xpert Ultra trace results?International Journal of Infectious Diseases, 2022
- Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy studyThe Lancet Respiratory Medicine, 2020
- Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of InfectionClinical Microbiology Reviews, 2018
- Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy studyThe Lancet Infectious Diseases, 2018
- The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care TestingmBio, 2017